IPO - Telomir Pharmaceuticals, Inc.

Form Type: S-3

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006943

Filing Summary: Telomir Pharmaceuticals, Inc. filed a registration statement with the SEC on February 14, 2025, under Form S-3. This registration allows the company to offer securities with a total aggregate initial offering price of up to $150,000,000, which may include common stock, preferred stock, warrants, and/or units. The company has plans to issue up to $100,000,000 of common stock under an At The Market Offering Agreement with Rodman & Renshaw LLC. The filing includes a base prospectus and will be supplemented with specific terms when securities are being offered. As a smaller reporting and emerging growth company, Telomir Pharmaceuticals benefits from reduced disclosure requirements. The document discusses the therapeutic potential of Telomir-1, a drug aimed at combating oxidative stress and related diseases by moderating essential metal ions, and includes details on risk factors and investment strategies related to their offerings. The company's common stock is listed on the Nasdaq under the symbol “TELO”.

Document Link: View Document